Novo Nordisk’s claim that a federal legal advisory opinion on 340B contract pharmacy would make it unlawfully transfer its drugs to ineligible pharmacies and ineligible patients “is mere legerdemain” (slight of hand), government lawyers for U.S. Health and Human Services (HHS) Secretary Xavier Becerra told a federal district judge in Trenton, N.J., Tuesday.
Chief Judge Freda Wolfson should either dismiss Novo Nordisk’s claims against Becerra over whether it must offer 340B pricing on drugs dispensed by contract pharmacies, or the judge should summarily decide the case in Becerra’s favor, the U.S. Justice Department (DOJ) said in a May 11 filing in the case.
Novo Nordisk’s claim that a federal legal advisory opinion on 340B contract pharmacy would make it unlawfully transfer its drugs to ineligible pharmacies and ineligible patients “is mere legerdemain” (slight of hand), government lawyers for U.S. Health and Human Services (HHS) Secretary Xavier Becerra told a federal district judge in Trenton, N.J., Tuesday.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.